Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

About Sarepta Therapeutics

Sarepta Therapeutics logoSarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company's lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SRPT
  • CUSIP:
Key Metrics:
  • Previous Close: $40.81
  • 50 Day Moving Average: $49.47
  • 200 Day Moving Average: $28.27
  • 52-Week Range: $8.00 - $63.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -20.20
  • P/E Growth: 51.10
  • Market Cap: $2.01B
  • Outstanding Shares: 47,899,000
  • Beta: 1.28
  • Return on Equity: -157.82%
  • Return on Assets: -106.30%
  • Debt-to-Equity Ratio: 0.10%
  • Current Ratio: 2.91%
  • Quick Ratio: 2.91%
Additional Links:
Companies Related to Sarepta Therapeutics:

Analyst Ratings

Consensus Ratings for Sarepta Therapeutics (NASDAQ:SRPT) (?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 13 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.74)
Consensus Price Target: $69.53 (70.37% upside)

Analysts' Ratings History for Sarepta Therapeutics (NASDAQ:SRPT)
DateFirmActionRatingPrice TargetDetails
10/27/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details
10/28/2016Royal Bank Of CanadaLower Price TargetOutperform$106.00View Rating Details
10/27/2016WedbushReiterated RatingOutperform$72.00View Rating Details
10/27/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$53.00View Rating Details
10/26/2016Leerink SwannReiterated RatingMarket Perform$50.00 -> $55.00View Rating Details
10/18/2016Credit Suisse Group AGInitiated CoverageOutperform$68.00View Rating Details
10/17/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$76.00View Rating Details
10/17/2016SunTrust Banks Inc.Reiterated RatingHold$52.00View Rating Details
10/17/2016RBC Capital MarketsReiterated RatingOutperform$108.00View Rating Details
10/17/2016Robert W. BairdReiterated RatingOutperform$102.00View Rating Details
10/8/2016Needham & Company LLCReiterated RatingBuy$81.00View Rating Details
10/5/2016Cowen and CompanyReiterated RatingOutperform$64.00View Rating Details
10/2/2016Jefferies GroupSet Price TargetHold$50.00 -> $58.00View Rating Details
10/2/2016William BlairReiterated RatingOutperform$88.00View Rating Details
9/28/2016JMP SecuritiesBoost Price TargetOutperform$60.00 -> $90.00View Rating Details
9/20/2016WBB SecuritiesReiterated RatingStrong-Buy$40.00 -> $60.00View Rating Details
9/19/2016Janney Montgomery ScottUpgradeNeutral -> Buy$30.00 -> $65.00View Rating Details
5/5/2016Ladenburg ThalmannDowngradeMarket Perform -> Underperform$13.00 -> $5.00View Rating Details
11/8/2015Roth CapitalReiterated RatingBuy$50.00View Rating Details
10/23/2015Bank of America Corp.Initiated CoverageBuy$49.00View Rating Details
9/1/2015SusquehannaBoost Price TargetNeutral$33.00 -> $36.00View Rating Details
5/23/2015Deutsche Bank AGReiterated RatingHold$24.00View Rating Details
5/20/2015Canaccord GenuityUpgradeHold -> Buy$16.00 -> $30.00View Rating Details
1/27/2015Northland SecuritiesUpgradeMarket Perform -> Outperform$3.00View Rating Details
(Data available from 10/28/2014 forward)


Earnings History for Sarepta Therapeutics (NASDAQ:SRPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2016Q316($1.32)($0.95)$1.06 millionViewListenView Earnings Details
7/19/2016Q2($1.19)($1.35)ViewN/AView Earnings Details
5/5/2016Q1($1.30)($1.15)$0.18 millionViewN/AView Earnings Details
2/24/2016Q4($1.18)($1.30)$1.25 millionViewN/AView Earnings Details
11/5/2015Q315($1.19)($1.25)ViewListenView Earnings Details
8/6/2015Q215($1.21)($1.01)$0.31 million$0.01 millionViewListenView Earnings Details
5/7/2015Q115($1.00)($1.49)$0.78 millionViewListenView Earnings Details
2/26/2015Q414($0.82)($0.94)$1.56 million$0.30 millionViewListenView Earnings Details
11/6/2014Q314($0.96)($0.70)$3.07 million$1.10 millionViewListenView Earnings Details
8/7/2014Q214($0.76)($0.85)$4.30 million$2.58 millionViewListenView Earnings Details
5/8/2014Q114($0.80)($0.75)$3.45 million$6.09 millionViewListenView Earnings Details
2/27/2014Q413($0.69)($0.77)$4.53 million$2.60 millionViewListenView Earnings Details
11/12/2013Q313($0.65)($0.63)$4.57 million$4.20 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.67)($0.46)$5.08 million$3.00 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.62)($0.41)$5.85 million$4.50 millionViewListenView Earnings Details
3/7/2013Q4 2012($0.26)($2.36)$6.71 million$7.30 millionViewListenView Earnings Details
11/7/2012($0.27)($2.17)$10.06 million$7.57 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sarepta Therapeutics (NASDAQ:SRPT)
Current Year EPS Consensus Estimate: $-5.34 EPS
Next Year EPS Consensus Estimate: $-2.02 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.40)($1.17)($1.29)
Q2 20165($1.32)($0.62)($1.08)
Q3 20166($1.41)($0.59)($1.10)
Q4 20166($1.25)($0.47)($0.97)
Q1 20171($1.15)($1.15)($1.15)
Q2 20171($1.02)($1.02)($1.02)
Q3 20171($0.99)($0.99)($0.99)
Q4 20171($0.97)($0.97)($0.97)
(Data provided by Zacks Investment Research)


Dividend History for Sarepta Therapeutics (NASDAQ:SRPT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Sarepta Therapeutics (NASDAQ:SRPT)
Insider Ownership Percentage: 10.90%
Institutional Ownership Percentage: 65.06%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/17/2016Sandesh MahatmeInsiderSell30,000$50.08$1,502,400.00View SEC Filing  
9/22/2016David T HowtonSVPSell7,000$60.00$420,000.00View SEC Filing  
9/22/2016Edward M Md KayeCEOSell40,179$60.00$2,410,740.00View SEC Filing  
9/19/2016David T HowtonSVPSell9,304$50.00$465,200.00View SEC Filing  
9/19/2016Edward M Md KayeCEOSell24,352$50.00$1,217,600.00View SEC Filing  
9/19/2016Jayant AphaleVPSell35,000$50.00$1,750,000.00View SEC Filing  
9/14/2016Edward M Md KayeCEOSell24,557$30.00$736,710.00View SEC Filing  
3/16/2016M Kathleen BehrensDirectorBuy10,000$14.54$145,400.00View SEC Filing  
3/14/2016M Kathleen BehrensDirectorBuy65,000$16.54$1,075,100.00View SEC Filing  
11/14/2013Anthony ChaseDirectorBuy10,000$13.95$139,500.00View SEC Filing  
9/16/2013M Kathleen BehrensDirectorBuy6,500$37.04$240,760.00View SEC Filing  
9/3/2013John HodgmanDirectorSell5,556$34.97$194,293.32View SEC Filing  
8/22/2013Anthony ChaseDirectorBuy3,500$32.68$114,380.00View SEC Filing  
8/20/2013Sandesh MahatmeCFOBuy5,000$31.10$155,500.00View SEC Filing  
6/14/2013Anthony R ChaseDirectorBuy10,000$38.50$385,000.00View SEC Filing  
9/7/2012M Kathleen BehrensDirectorBuy17,500$14.73$257,775.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Sarepta Therapeutics (NASDAQ:SRPT)
News IconSarepta Therapeutics Inc. (SRPT) Stock: Jason Karp Is A Shareholder Again And Has A Larger Position Than Ever (NASDAQ:SRPT) - October 28 at 1:40 PM
News IconRunning Mover to Focus- Sarepta Therapeutics, Inc.'s (SRPT) - Hot Stocks Point (NASDAQ:SRPT) - October 28 at 11:29 AM logoSarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3 (NASDAQ:SRPT) - October 28 at 11:29 AM logoSarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : October 28, 2016 (NASDAQ:SRPT) - October 28 at 11:29 AM
News IconSarepta Therapeutics reports 3Q loss - Yahoo Sports (NASDAQ:SRPT) - October 27 at 7:38 PM logoEarnings Reaction History: Sarepta Therapeutics, Inc., 71.4% Follow-Through Indicator, 10.5% Sensitive - Nasdaq (NASDAQ:SRPT) - October 27 at 7:38 PM logoWhy Sarepta is Sinking (NASDAQ:SRPT) - October 27 at 7:38 PM
News IconSizing Up Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Earnings as Analysts Take Aim at Projections - CSZ News (NASDAQ:SRPT) - October 27 at 12:36 PM logoSarepta Therapeutics reports 3Q loss (NASDAQ:SRPT) - October 27 at 12:36 PM logoNotable Wednesday Option Activity: SRPT, BOFI, ORLY (NASDAQ:SRPT) - October 26 at 7:30 PM
News IconTime To Put On The Watch List? - Sarepta Therapeutics (NASDAQ:SRPT), Array BioPharma (NASDAQ:ARRY) - The Voice Registrar (NASDAQ:SRPT) - October 26 at 11:02 AM
News IconAnalysts give average Rating of “Buy” to Sarepta Therapeutics Inc. (SRPT) - DailyQuint (NASDAQ:SRPT) - October 26 at 11:02 AM
News IconTwo Biotech Stocks Are Just So Hot Right Now: ContraVir Pharmaceuticals, Inc. (CTRV), Sarepta Therapeutics, Inc ... - The Independent Republic (NASDAQ:SRPT) - October 25 at 11:34 AM
News IconAnalysts Valuations For Two Stocks: Paycom Software (NYSE:PAYC), Sarepta Therapeutics (NASDAQ:SRPT) - The Voice Registrar (NASDAQ:SRPT) - October 25 at 11:34 AM
News IconBiotech news that matter for investors: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), ImmunoGen, Inc. (NASDAQ:IMGN) - The Voice Registrar (NASDAQ:SRPT) - October 25 at 11:34 AM
News IconSizzling Stocks Alert – Freeport-McMoRan, (NYSE:FCX), Sarepta Therapeutics, (NASDAQ:SRPT) - Money News (NASDAQ:SRPT) - October 24 at 7:06 PM
News IconAnalysts Rating Stocks in Focus: Sarepta Therapeutics Inc ... - Money News (NASDAQ:SRPT) - October 24 at 11:51 AM logoSarepta Therapeutics to Announce Third Quarter 2016 Financial Results and Recent Corporate Developments on October 27, 2016 (NASDAQ:SRPT) - October 24 at 11:51 AM
News IconRBC Capital Markets Reiterates "Outperform" Rating for Sarepta Therapeutics Inc. (SRPT) (NASDAQ:SRPT) - October 21 at 7:28 PM logoTrader Alert: Sarepta Therapeutics, Inc. (SRPT), ON Semiconductor Corp. (ON), Berkshire Hathaway Inc. (BRK-B) - iStreetWire (NASDAQ:SRPT) - October 21 at 11:02 AM
News IconActive biotech company shares in the news: Sarepta Therapeutics (NASDAQ:SRPT), Puma Biotechnology (NYSE:PBYI) - The Voice Registrar (NASDAQ:SRPT) - October 21 at 11:02 AM
News IconIntraday Active Biotech Stocks News: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), CytRx Corporation (NASDAQ:CYTR) - The Voice Registrar (NASDAQ:SRPT) - October 20 at 12:36 PM
News IconTraders Recap: Sarepta Therapeutics Inc (NASDAQ:SRPT) - Post Registrar (NASDAQ:SRPT) - October 20 at 12:36 PM
News IconTwo Biotechnology Names Are Hot: ACADIA Pharmaceuticals Inc. (ACAD), Sarepta Therapeutics, Inc. (SRPT) - The Independent Republic (NASDAQ:SRPT) - October 20 at 12:36 PM logoFor Sarepta, Exondys 51 Might Be Just The Beginning: Credit Suisse Starts At Outperform (NASDAQ:SRPT) - October 18 at 12:25 PM logoCredit Suisse Initiates Coverage on Sarepta Therapeutics Inc (SRPT) as Outperform (NASDAQ:SRPT) - October 18 at 12:25 PM logoSarepta Therapeutics: If You Approve It They Will Come (NASDAQ:SRPT) - October 18 at 12:25 PM
News IconWhat are Analysts Expecting for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Earnings? - CSZ News (NASDAQ:SRPT) - October 17 at 7:17 PM logoExclusive: SunTrust Managing Director Goes Over Sarepta ... - Benzinga (NASDAQ:SRPT) - October 17 at 7:17 PM logoExclusive: SunTrust Managing Director Goes Over Sarepta Therapeutics' Story (NASDAQ:SRPT) - October 17 at 11:48 AM logoSarepta Therapeutics' Greatest Threat: Anthem? (NASDAQ:SRPT) - October 17 at 9:28 AM
News IconUpdate on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for the day (NASDAQ:SRPT) - October 15 at 7:00 PM
News IconSarepta Therapeutics Inc. to Post FY2020 Earnings of $2.37 Per Share, Wedbush Forecasts (SRPT) - DailyQuint (NASDAQ:SRPT) - October 14 at 7:16 PM logoHere's Why This Top Analyst Is Positive on Sarepta Therapeutics Inc (SRPT) - Smarter Analyst (NASDAQ:SRPT) - October 14 at 7:16 PM logoShort Interest In Sarepta Therapeutics Moves 21% Lower (NASDAQ:SRPT) - October 13 at 7:39 PM logoHere’s Why This Top Analyst Is Positive on Sarepta Therapeutics Inc (SRPT) (NASDAQ:SRPT) - October 13 at 7:39 PM
News IconStock Roundup - Sarepta Therapeutics, Inc.'s (SRPT) - Hot Stocks Point (NASDAQ:SRPT) - October 12 at 8:55 AM
News IconTop Biotechnology Stock Picking: Northwest Biotherapeutics, Inc. (NWBO), Sarepta Therapeutics, Inc. (SRPT) - The Independent Republic (NASDAQ:SRPT) - October 12 at 8:55 AM
News IconActive Biotech Stock News: Intra-Cellular Therapies, Inc. (ITCI ... - The Independent Republic (NASDAQ:SRPT) - October 11 at 8:18 PM logoWhy Sarepta Therapeutics Skyrocketed 131% in September (NASDAQ:SRPT) - October 11 at 3:45 PM
News IconSarepta Therapeutics Inc. (SRPT) Receives Outperform Rating from Wedbush (NASDAQ:SRPT) - October 11 at 3:15 PM logoHealth insurers split on coverage of Sarepta’s Duchenne drug (NASDAQ:SRPT) - October 11 at 12:53 PM
News IconEmerald Advisers Inc. PA Takes Position in Sarepta Therapeutics Inc. (SRPT) (NASDAQ:SRPT) - October 10 at 6:54 PM logoSarepta Therapeutics Inc (SRPT) PT Increased to $72, Reiterated as Outperform (NASDAQ:SRPT) - October 10 at 6:54 PM logoSarepta Tumbles After Anthem’s Refusal (SRPT, ANTM) (NASDAQ:SRPT) - October 10 at 6:54 PM
News IconBetter Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc. - (NASDAQ:SRPT) - October 10 at 11:42 AM
News IconWorth Watching Stocks in the News: Sarepta Therapeutics Inc(NASDAQ:SRPT), Harvest Natural Resources, Inc.(NYSE ... - NYSE Journal (press release) (NASDAQ:SRPT) - October 10 at 11:42 AM
News IconScorching Hot Biotech Stocks Tape: Gilead Sciences Inc. (GILD), Sarepta Therapeutics, Inc. (SRPT) - The Independent Republic (NASDAQ:SRPT) - October 10 at 11:42 AM logoBetter Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - October 10 at 10:12 AM
News IconFreeport-McMoRan Inc (NYSE:FCX) & Sarepta Therapeutics Inc (NASDAQ:SRPT) Stocks to Keep Your Eyes on (NASDAQ:SRPT) - October 8 at 11:42 AM


Sarepta Therapeutics (NASDAQ:SRPT) Chart for Friday, October, 28, 2016

Last Updated on 10/28/2016 by Staff